top of page

FDA approves Novo Nordisk Awiqli as first once-weekly basal insulin for children with type 2 diabetes

Immagine del redattore: nuaxia
nuaxia
28 ott
Tempo di lettura: 2 min

The FDA has expanded Novo Nordisk's Awiqli approval to children aged 10 years and older with type 2 diabetes, establishing the first once-weekly basal insulin option for this paediatric population.


Awiqli (insulin icodec-abae) is now authorised as a once-weekly subcutaneous basal insulin for eligible children with type 2 diabetes as an adjunct to diet and exercise, extending its previously approved adult indication.


The paediatric decision was supported by pharmacokinetic data from 18 patients and pharmacometric modelling, providing an additional insulin administration option that may reduce injection frequency compared with daily basal insulin regimens.

Field

Content

Article Type

Approvals

Regulatory Authority

U.S. Food and Drug Administration

Regulatory Decision

Paediatric indication expansion

Approval Announcement Date

23 October 2026

Company

Novo Nordisk

Drug Name

Awiqli

Generic Name

Insulin icodec-abae

Drug Class

Long-acting basal insulin

Therapeutic Area

Endocrinology; diabetes

Approved Indication

Type 2 diabetes mellitus in children aged 10 years and older as an adjunct to diet and exercise

Patient Population

Paediatric patients aged 10 years and older with type 2 diabetes

Administration Route

Subcutaneous injection

Dosing Frequency

Once weekly

Regulatory Significance

First once-weekly insulin approved for paediatric type 2 diabetes in the United States

Previous Approved Population

Adults with type 2 diabetes

Supporting Evidence

Paediatric pharmacokinetic data and pharmacometric modelling

Paediatric Pharmacokinetic Study Population

18 patients

Comparative Efficacy Results

Not provided in supplied summary

Geography

United States

What Happened

The FDA expanded Awiqli's approved use to children aged 10 years and older with type 2 diabetes.

Why It Matters

The decision introduces a once-weekly basal insulin option for eligible paediatric patients and may reduce treatment administration burden.

Clinical Evidence

The paediatric approval was supported by pharmacokinetic observations in 18 patients and pharmacometric modelling.

Regulatory Distinction

This is a new paediatric indication rather than a repeat of the existing adult approval.

Key Takeaway

Awiqli is the first FDA-approved once-weekly basal insulin for children aged 10 years and older with type 2 diabetes.

What to Watch

Updated paediatric prescribing guidance, dosing implementation, clinician adoption, reimbursement and real-world safety outcomes.

Primary Source

U.S. Food and Drug Administration

Primary Source URL

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-once-weekly-insulin-type-2-diabetes-mellitus-pediatric-patients

Relevant Date

23 October 2026


Discover how nuaxia can support your next medical education initiative:

 
 
 

Commenti

Valutazione 0 stelle su 5.
Non ci sono ancora valutazioni

Aggiungi una valutazione
bottom of page